The Microcirculation in Acute Myocardial Infarction (Micro-AMI)

This study is currently recruiting participants. (see Contacts and Locations)
Verified July 2013 by University of Bristol
Sponsor:
Collaborators:
David Telling Charitable Trust
NIHR Cardiovascular BRU
Information provided by (Responsible Party):
Elisa McAlindon, University of Bristol
ClinicalTrials.gov Identifier:
NCT01552564
First received: March 9, 2012
Last updated: July 8, 2013
Last verified: July 2013
  Purpose

This study investigates the association between the microvascular resistance at the time of primary percutaneous intervention, with microvascular obstruction on CMR and blood markers of myocardial damage.


Condition Intervention
STEMI
Procedure: Index of microvascular resistance
Other: Cardiac magnetic resonance
Other: Blood markers

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: The Microcirculation in Acute Myocardial Infarction (Micro-AMI)

Resource links provided by NLM:


Further study details as provided by University of Bristol:

Primary Outcome Measures:
  • Microvascular obstruction [ Time Frame: DAy 2-4 ] [ Designated as safety issue: No ]
    Microvascular obstruction as a percentage of the left ventricle at 2-4 days.


Estimated Enrollment: 50
Study Start Date: March 2012
Groups/Cohorts Assigned Interventions
STEMI patients Procedure: Index of microvascular resistance Other: Cardiac magnetic resonance Other: Blood markers

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

STEMI attending Bristol Heart Institute via the primary PCI service

Criteria

Inclusion Criteria:

  • >18 years old
  • Cardiac symptoms of > 20 mins chest pain or equivalent.
  • ECG criteria consistent with STEMI (STEMI)
  • Proceeding with percutaneous angioplasty
  • Assent/ consent to the study

Exclusion Criteria:

  • Known allergy to adenosine or gadolinium
  • Chronic atrial fibrillation
  • Renal impairment with eGFR <30
  • Contraindication to angiography
  • Contraindication to CMR (implanted pacemaker/ defibrillator, ferromagnetic metal implant/ injury, claustrophobia, obesity/ too large for CMR scanner)
  • Cardiogenic shock
  • Patients with special communication needs or altered consciousness.
  • Patients who do not give assent/consent to the study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01552564

Contacts
Contact: Elisa McAlindon, BMBS 01173425888 elisa.mcalindon@bristol.ac.uk

Locations
United Kingdom
Bristol Heart Institute Recruiting
Bristol, United Kingdom, BS2 8HW
Sponsors and Collaborators
University of Bristol
David Telling Charitable Trust
NIHR Cardiovascular BRU
  More Information

No publications provided

Responsible Party: Elisa McAlindon, Clinical Research Fellow, University of Bristol
ClinicalTrials.gov Identifier: NCT01552564     History of Changes
Other Study ID Numbers: 1625
Study First Received: March 9, 2012
Last Updated: July 8, 2013
Health Authority: United Kingdom: National Institute for Health Research

Additional relevant MeSH terms:
Infarction
Myocardial Infarction
Ischemia
Pathologic Processes
Necrosis
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Vascular Diseases

ClinicalTrials.gov processed this record on July 29, 2014